MAPT and Alzheimer disease: This has led to the proposal of adding neuroinflammatory biomarkers as “I” to the conventional classification system based on amyloid, tau, and neurodegeneration to describe the progression of AD (amyloid, tau, neurodegeneration (ATN) classification) [14] to the proposed ATN(I) classification [15].